Ester Prodrug NLRP3 Inflammasome Inhibitor NT-0796 is Brain Active due to Activation by Local Expression of Carboxylesterase-1

Read full text
Authors: Zsofia Digby, Christine Diamond, Heather Wescott, Pam Smolak, Peter Thornton, Nicola Lindsay, Christopher A. Gabel, Nicholas Clarke, Alan P. Watt
Cited by: 4
References: 53

Abstract

High Resolution Image Download MS PowerPoint Slide NLRP3 inflammasome activation has been implicated in the pathogenesis of human disorders, including a number of neurodegenerative diseases of the central nervous system. Pharmacological inhibition of NLRP3-mediated neuroinflammation via a brain-penetrant therapeutic agent, therefore, is an attractive target for the treatment of neurodegenerative disorders. The NLRP3 inflammasome inhibitor NT-0796 is an ester-containing prodrug that is metabolized intracellularly into its active metabolite NDT-19795 by carboxylesterase-1 (CES1). NT-0796 shows high in vitro permeability in an induced pluripotent stem cells (iPSC)-derived human brain endothelial blood–brain barrier (BBB) model, while nonhuman primate pharmacokinetics studies demonstrate the ability of NT-0796 to cross the BBB, which is then metabolized locally to give rise to its active metabolite, NDT-19795 in vivo . While human and nonhuman primate cerebrospinal fluid are incapable of NT-0796 metabolism, brain parenchymal tissue homogenates obtained from either species metabolized NT-0796 to NDT-19795. Data presented in this manuscript also offer a mechanistic explanation for the central exposure levels of NDT-19795 achieved following NT-0796 administration in our Phase 1b open-label study conducted in elderly healthy volunteers and patients with Parkinson’s disease, recently published in Movement Disorders. Immunolocalization of nonhuman primate frontal tissues indicates that CES1 is expressed by a subpopulation of cells, many of which were also ionized calcium-binding adapter molecule 1 (IBA1) positive. Collectively, these data show that the ester-containing prodrug, NT-0796, is highly brain penetrant and, after crossing the BBB, NT-0796 is metabolized predominantly by CES1 in brain parenchyma. Immunolocalization studies also suggest that the subset of cells in the brain expressing CES1 is microglial in origin.

Fields of Study & Subjects

Cholinesterase and Neurodegenerative Diseases Phosphodiesterase function and regulation Alzheimer's disease research and treatments

Publication details

Journal / source
ACS Chemical Neuroscience
Publisher
American Chemical Society (ACS)
Volume
17
Issue
3
Pages
599–609
Publication date
26 January 2026
Language
EN